STOCK TITAN
  1. Home
  2. News
  3. MDNA

Medicenna Therapeutics Corp - MDNA STOCK NEWS

Welcome to our dedicated news page for Medicenna Therapeutics (Ticker: MDNA), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medicenna Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medicenna Therapeutics's position in the market.

News
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting
Rhea-AI Summary
Medicenna Therapeutics Corp. (MDNA) to present long-term follow-up data from Phase 2b clinical trial of bizaxofusp at SNO 2023 Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.54%
Tags
conferences clinical trial
-
News
Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Rhea-AI Summary
Medicenna Therapeutics Corp. presented new clinical data from the Phase 1 monotherapy dose escalation/evaluation portion of the ABILITY-1 study at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The data showed encouraging single-agent activity of MDNA11, with deep partial responses and durable stable disease in advanced solid tumor patients. MDNA11 demonstrated a favorable safety profile with no dose-limiting toxicities reported. The recommended dose for expansion in the monotherapy portion of the study is 90 ug/kg. Results from the Phase 2 study are expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.52%
Tags
clinical trial
-
News
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Rhea-AI Summary
Medicenna Therapeutics Corp. announced preclinical data demonstrating proof of concept for its T-MASK platform technology with its development candidate, MDNA113. The platform enhances tumor specific accumulation and anti-tumor activity while improving the safety profile of immune modulators. MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment. The IL-13Rα2 target is linked to aggressive cancers that affect over 2 million patients annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
48.02%
Tags
clinical trial
News
Medicenna Announces Nasdaq Delisting and Cutback of Management Team
Rhea-AI Summary
Medicenna Therapeutics Corp. has received a delisting determination from Nasdaq due to its failure to comply with the minimum bid price requirement. The company will not appeal the decision and its common shares will continue to trade on the TSX. The decision was made to save costs and resources associated with a Nasdaq listing. The company anticipates significant financial savings as a result of this decision. The company will also seek to have its common shares traded on the OTC Markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.51%
Tags
none
-
News
Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors
Rhea-AI Summary
Medicenna announces dosing of first patient in Phase 2 study for MDNA11
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.11%
Tags
clinical trial
-
News
Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)
Rhea-AI Summary
Medicenna Therapeutics Corp. will present an update from its Phase 1/2 ABILITY Study at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. They will also present pre-clinical data for MDNA113, a novel tumor-targeted and tumor-activated bi-functional anti-PD1-IL-2 superkine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
none
News
Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
Rhea-AI Summary
Medicenna Therapeutics Corp. appoints Humphrey Gardner, M.D. as Chief Medical Officer to lead the development of clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.45%
Tags
management
-
News
Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy
Rhea-AI Summary
Medicenna Therapeutics Corp. presents preclinical data on MDNA223, a bifunctional Superkine for immunotherapy, at AACR Special Conference. MDNA223 shows superior efficacy and extended survival in multiple tumor models, including 'cold' tumors. It demonstrates synergy with pro-inflammatory agonist (STING) and enhances tumor inhibition and abscopal effect. The data highlight the potential of Medicenna's BiSKIT platform for effective therapy in challenging-to-treat tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
none
-
News
Medicenna Announces Results of Annual and Special Meeting of Shareholders
Rhea-AI Summary
Medicenna announces successful election of directors with over 97% of votes cast, positive for stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.73%
Tags
none
News
Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy
Rhea-AI Summary
Medicenna to present preclinical results of MDNA223 BiSKIT candidate at AACR Special Conference in Cancer Research. Management to participate in upcoming healthcare and partnering summits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
conferences
Stock MDNA logo
Medicenna Therapeutics Corp

Nasdaq:MDNA

MDNA Rankings

N/A Ranked by Market Cap
#5212 Ranked by Stock Gains
N/A Ranked by Dividends

MDNA Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About MDNA

medicenna is a clinical stage immunotherapy company developing novel highly selective versions of il-2, il-4 and il-13 superkines and first in class empowered cytokines (ecs). our mission is to become the leader in the development and commercialization of targeted ecs and superkines for the treatment of a broad range of cancers and immune-mediated diseases. we seek to achieve these successful treatments by drawing on our expertise, and that of world-class collaborators, to develop a unique set of superkines. these superkines can be developed either on their own as short or long-acting therapeutics or fused with pro-apoptotic proteins in order to precisely deliver potent cell-killing agents to the cancer cells as well as the immunosuppressive tumor micro-environment and the cancer stem cells without harming healthy cells. superkines can also be fused with other types of proteins such as antibodies to generate novel “immunocytokines” or combined with other treatment modalities such as ca